ATE293883T1 - Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen - Google Patents

Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen

Info

Publication number
ATE293883T1
ATE293883T1 AT97901425T AT97901425T ATE293883T1 AT E293883 T1 ATE293883 T1 AT E293883T1 AT 97901425 T AT97901425 T AT 97901425T AT 97901425 T AT97901425 T AT 97901425T AT E293883 T1 ATE293883 T1 AT E293883T1
Authority
AT
Austria
Prior art keywords
antioxidants
liver disease
cholestatic liver
treat cholestatic
treat
Prior art date
Application number
AT97901425T
Other languages
English (en)
Inventor
Ronald J Sokol
Original Assignee
Ronald J Sokol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ronald J Sokol filed Critical Ronald J Sokol
Application granted granted Critical
Publication of ATE293883T1 publication Critical patent/ATE293883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97901425T 1996-01-16 1997-01-15 Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen ATE293883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1004996P 1996-01-16 1996-01-16
PCT/US1997/000403 WO1997025864A1 (en) 1996-01-16 1997-01-15 Use of antioxidant agents to treat cholestatic liver disease

Publications (1)

Publication Number Publication Date
ATE293883T1 true ATE293883T1 (de) 2005-05-15

Family

ID=21743557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901425T ATE293883T1 (de) 1996-01-16 1997-01-15 Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen

Country Status (7)

Country Link
US (1) US6069167A (de)
EP (1) EP0893949B1 (de)
AT (1) ATE293883T1 (de)
AU (1) AU724620B2 (de)
CA (1) CA2242991C (de)
DE (1) DE69733132D1 (de)
WO (1) WO1997025864A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US6855733B2 (en) * 2001-01-24 2005-02-15 Soft Gel Technologies, Inc. Formulation and manufacturing process for coenzyme Q10 soft gel capsules
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050074444A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Coenzyme Q10 treatment for cystic fibrosis
US20050107465A1 (en) * 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
TW200524579A (en) * 2003-11-28 2005-08-01 Kaneka Corp Composition for protecting liver functions
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
DE102004049339A1 (de) * 2004-10-08 2006-04-13 Basf Ag Verfahren zur Reinigung von phosphorhaltigen Chelat-Liganden
WO2006092449A2 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
EP2063905B1 (de) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
WO2008116171A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
EP2346519B1 (de) 2008-10-02 2015-12-02 George Zabrecky Verfahren und formulierungen zur behandlung von chronischer lebererkrankung
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
DK2637646T3 (en) * 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CN108601739B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069247B1 (de) 2019-12-04 2025-03-26 Albireo AB Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
IL293379B2 (en) 2019-12-04 2026-04-01 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
EP4188541B1 (de) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59502024A (ja) * 1982-11-16 1984-12-06 イレナ　モッチャン　マルス リュウマチ性疾病治療剤
DE69122099T2 (de) * 1990-05-16 1997-04-17 Margaret Hanausek Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
WO1993013660A1 (en) * 1992-01-06 1993-07-22 Health Maintenance Programs, Inc. Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty
CN1080855A (zh) * 1993-05-22 1994-01-19 黎均耀 维生素矿物质防癌复方
DE4322070A1 (de) * 1993-07-02 1995-01-12 Ploch Eva Marina Umweltkapsel

Also Published As

Publication number Publication date
AU724620B2 (en) 2000-09-28
AU1532997A (en) 1997-08-11
CA2242991A1 (en) 1997-07-24
DE69733132D1 (de) 2005-06-02
WO1997025864A1 (en) 1997-07-24
EP0893949A4 (de) 2002-01-02
EP0893949B1 (de) 2005-04-27
CA2242991C (en) 2007-07-24
US6069167A (en) 2000-05-30
EP0893949A1 (de) 1999-02-03

Similar Documents

Publication Publication Date Title
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE69523745D1 (de) Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
MD990262A (en) Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease
DK0920309T3 (da) Konjugeret linolensyre til bevaring eller forøgelse af mineralindhold i knogler
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE303817T1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
DE69739970D1 (de) Methode zur behandlung sexueller fehlfunktionen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties